Identifying inhibitors for specific proteins involved in immune cell signaling
A high-throughput platform to identify selective allosteric inhibitors of the PLC-y isozymes
This study is looking at how two proteins that help control immune cells might be involved in blood cancers, and it's trying to find new treatments that can specifically target these proteins to help improve care for patients with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10815854 on NIH RePORTER |
What this research studies
This research focuses on understanding how two specific proteins, PLC-gamma1 and PLC-gamma2, regulate immune cell signaling, particularly in B and T cells. By developing a high-throughput platform, the researchers aim to identify selective inhibitors that can target these proteins, which are often mutated in various blood cancers. The approach involves using advanced techniques to monitor the regulation of these proteins and their response to external stimuli. Patients may benefit from new therapeutic options that specifically target these proteins, potentially improving treatment outcomes for blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with blood cancers, such as leukemias and lymphomas, particularly those with mutations in PLC-gamma isozymes.
Not a fit: Patients with solid tumors or those without mutations in PLC-gamma isozymes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with blood cancers, improving their treatment options and outcomes.
How similar studies have performed: Previous research has shown promise in targeting similar proteins in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Zhang, Qisheng — Univ of North Carolina Chapel Hill
- Study coordinator: Zhang, Qisheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.